Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses and Dose Titration of Bexicaserin in Healthy Participants in a Randomized, Double‐Blind, Placebo‐Controlled Study
Clinical Pharmacology in Drug Development · 2026
DOI: 10.1002/cpdd.1602 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2026. Verfasst von Jonathan Williams und 7 weiteren Autor:innen. Beteiligte Einrichtung: Lundbeck LLC, Deerfield, IL, USA. Hauptthemen laut MEDLINE: Serotonin 5-HT2 Receptor Agonists. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Longboard Pharmaceuticals, Lundbeck, H. Lundbeck A/S.
Abstract (Originalsprache)
Bexicaserin (LP352) is a selective superagonist of the 5‐hydroxytryptamine 2C (5‐HT 2C ) receptor currently in development for the treatment of seizures that arise from developmental and epileptic encephalopathies. This phase 1, double‐blind, placebo‐controlled multiple ascending dose (MAD) study assessed the safety, tolerability, and pharmacokinetic profile of bexicaserin in healthy participants. Doses ranging from 3 to 24 mg three times daily (TID) were administered for up to 14 days. Serial blood and urine samples were collected to assess pharmacokinetics, and prolactin was assessed as a pharmacodynamic biomarker. Bexicaserin was generally safe and well‐tolerated, rapidly absorbed, metabolized to three circulatory pharmacologically inactive metabolites, and had a median T max of about 1–2 h. C max accumulation ranged from 1.5 to 5.1‐fold for all analytes after multiple doses. M20 was the major metabolite, with exposures ranging from 9 to 33‐fold versus bexicaserin. Overall clearance of bexicaserin ranged from 45.9 to 125 L/h, with renal clearance between 5.04 to 6.58 L/h, suggesting that hepatic metabolism and/or excretion is the main elimination pathway. There was a weak dose‐dependent positive correlation between bexicaserin C max and prolactin mean percentage change from baseline, suggesting successful engagement of central 5‐HT 2C receptors. Overall, this Phase 1 MAD study demonstrated bexicaserin to be safe and well‐tolerated, with rapid absorption, presence of one major metabolite, accumulation upon multiple dosing TID, and a greater than dose‐proportional increase in exposures. These findings support the continued development of bexicaserin, which is currently in Phase 3 clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lundbeck LLC, Deerfield, IL, USA.
- Longboard Pharmaceuticals (now part of Lundbeck LLC), La Jolla, CA, USA.
- Lundbeck Ltd, Watford, UK.
Förderung
- Longboard Pharmaceuticals
- Lundbeck
- H. Lundbeck A/S
Zitieren
APA
Williams, J., Chan, R., Orevillo, C., O'Connell, G., McLin, D., Polega, S., Srinivas, N. R., & Kaye, R. (2026). Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses and Dose Titration of Bexicaserin in Healthy Participants in a Randomized, Double‐Blind, Placebo‐Controlled Study. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1602
Vancouver
Williams J, Chan R, Orevillo C, O'Connell G, McLin D, Polega S, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses and Dose Titration of Bexicaserin in Healthy Participants in a Randomized, Double‐Blind, Placebo‐Controlled Study. Clinical Pharmacology in Drug Development. 2026. doi:10.1002/cpdd.1602
BibTeX
@article{Williams2026,
author = {Williams, Jonathan and Chan, Rosa and Orevillo, Chad and O'Connell, Gale and McLin, Dewey and Polega, Shikha and Srinivas, Nuggehally R and Kaye, Randall},
title = {Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses and Dose Titration of Bexicaserin in Healthy Participants in a Randomized, Double‐Blind, Placebo‐Controlled Study},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
doi = {10.1002/cpdd.1602}
}
EUVIMED